The approval of CD19-directed CAR-T cells by the FDA for the treatment of relapsed or refractory pediatric and young adult diffuse large B cell lymphoma (DLBCL) further validates the effectiveness of this approach [29, 51]. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.